The Global Enzymatic Wound Debridement Market size is expected to reach $1.3 billion by 2030, rising at a market growth of 6.4% CAGR during the forecast period.
In pressure ulcers, where infection is a common complication, maintaining a clean wound bed through enzymatic debridement is crucial for preventing localized and systemic infections. Therefore, the pressure ulcers segment captured $153.2 million revenue in the market in 2022. Enzymatic debridement helps reduce the risk of infection by eliminating the necrotic tissue that can serve as a breeding ground for bacteria. Pressure ulcers can be particularly challenging to manage due to the risk of further trauma to the compromised skin. Enzymatic debridement provides a minimally invasive approach, minimizing additional damage to the vulnerable tissue. Some of the factors impacting the market are advancements in enzyme formulations, growing incidence of chronic wounds and high cost of enzymatic debridement products.
Advancements in enzyme formulations often focus on enhancing the stability of enzymes. Enzymes can be sensitive to environmental conditions, and maintaining their stability is crucial for product effectiveness. Improved stability allows for a longer shelf life and better performance of enzymatic debridement products, contributing to their reliability in clinical settings. Advanced enzyme formulations often result in increased efficacy of enzymatic debridement products. Additionally, enzymatic debridement offers a cost-efficient option for managing chronic wounds, especially in outpatient settings. As healthcare systems globally strive to optimize resource utilization and shift toward providing care outside traditional hospital settings, enzymatic debridement becomes a valuable tool in the outpatient care landscape. Therefore, the increasing incidence of chronic wounds is a key driver that positively expands the market.
However, as healthcare systems worldwide faced surges in COVID-19 cases during the pandemic, there was a significant shift in priorities toward managing the pandemic. Non-essential medical procedures, including certain wound care treatments, were postponed. This delay had affected the adoption of enzymatic wound debridement in some cases, particularly for wounds that were not deemed urgent. The emphasis on infection control during the pandemic had likely influenced wound care practices, including debridement strategies. The adoption of telehealth and home-based care had surged during the pandemic. Enzymatic wound debridement had benefited from this trend with its potential for use in home care settings. Patients who were unable or hesitant to visit healthcare facilities had sought alternative solutions for wound management, leading to increased interest in home-based enzymatic debridement options. Therefore, the pandemic had a positive impact on the market.
Moreover, the upfront cost of enzymatic debridement products may be a barrier to adoption, particularly in healthcare systems with limited financial resources. Hospitals, clinics, and other healthcare establishments may be cautious about investing in these products, especially if they perceive them as expensive compared to alternative debridement methods. Healthcare providers often evaluate the cost-effectiveness of different wound care interventions. The perceived high cost of enzymatic debridement products may lead to comparisons with alternative debridement methods, such as surgical or mechanical. The economic considerations may influence decision-making in favor of more cost-efficient options. Due to the above factors, market growth will be hampered in the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd.
In pressure ulcers, where infection is a common complication, maintaining a clean wound bed through enzymatic debridement is crucial for preventing localized and systemic infections. Therefore, the pressure ulcers segment captured $153.2 million revenue in the market in 2022. Enzymatic debridement helps reduce the risk of infection by eliminating the necrotic tissue that can serve as a breeding ground for bacteria. Pressure ulcers can be particularly challenging to manage due to the risk of further trauma to the compromised skin. Enzymatic debridement provides a minimally invasive approach, minimizing additional damage to the vulnerable tissue. Some of the factors impacting the market are advancements in enzyme formulations, growing incidence of chronic wounds and high cost of enzymatic debridement products.
Advancements in enzyme formulations often focus on enhancing the stability of enzymes. Enzymes can be sensitive to environmental conditions, and maintaining their stability is crucial for product effectiveness. Improved stability allows for a longer shelf life and better performance of enzymatic debridement products, contributing to their reliability in clinical settings. Advanced enzyme formulations often result in increased efficacy of enzymatic debridement products. Additionally, enzymatic debridement offers a cost-efficient option for managing chronic wounds, especially in outpatient settings. As healthcare systems globally strive to optimize resource utilization and shift toward providing care outside traditional hospital settings, enzymatic debridement becomes a valuable tool in the outpatient care landscape. Therefore, the increasing incidence of chronic wounds is a key driver that positively expands the market.
However, as healthcare systems worldwide faced surges in COVID-19 cases during the pandemic, there was a significant shift in priorities toward managing the pandemic. Non-essential medical procedures, including certain wound care treatments, were postponed. This delay had affected the adoption of enzymatic wound debridement in some cases, particularly for wounds that were not deemed urgent. The emphasis on infection control during the pandemic had likely influenced wound care practices, including debridement strategies. The adoption of telehealth and home-based care had surged during the pandemic. Enzymatic wound debridement had benefited from this trend with its potential for use in home care settings. Patients who were unable or hesitant to visit healthcare facilities had sought alternative solutions for wound management, leading to increased interest in home-based enzymatic debridement options. Therefore, the pandemic had a positive impact on the market.
Moreover, the upfront cost of enzymatic debridement products may be a barrier to adoption, particularly in healthcare systems with limited financial resources. Hospitals, clinics, and other healthcare establishments may be cautious about investing in these products, especially if they perceive them as expensive compared to alternative debridement methods. Healthcare providers often evaluate the cost-effectiveness of different wound care interventions. The perceived high cost of enzymatic debridement products may lead to comparisons with alternative debridement methods, such as surgical or mechanical. The economic considerations may influence decision-making in favor of more cost-efficient options. Due to the above factors, market growth will be hampered in the coming years.
End Use Outlook
By end-use, the market is categorised into hospitals, homecare, and others. In 2022, the hospitals segment generated the highest revenue share in the market. The increased prevalence of chronic lesions globally is the cause of this observation. Another factor propelling segment growth is the escalating numbers of diabetic foot ulcers and venous leg ulcers. The escalating prevalence of surgical incisions can be attributed to the surge in surgical procedures. It is also utilized to treat surgical site infections. Consequently, segment growth may be fueled by these factors throughout the forecast period.Type Outlook
On the basis of type, the market is segmented into chronic wounds and acute wounds. The chronic wounds segment garnered a significant revenue share in the market in 2022. Pressure, diabetic foot, and venous leg ulcers are all examples of chronic lesions. Compared to other chronic wounds, the pressure ulcers segment is projected to share the rapid expansion during the forecast period. Bed sores, also called pressure ulcers, are typically the result of protracted, intense pressure on the skin. Extended hospitalization is the prevailing etiology factor for these ulcers. They are prevalent among older people and appear most frequently in bony regions, including the ankles, hips, and tailbone. Increasing geriatric populations worldwide are a significant factor in segment expansion.Product Outlook
Based on product, the market is classified into collagenase product, papain product, and others. In 2022, the collagenase product segment witnessed the largest revenue share in the market. Enzymatic debridement products, including ointments, creams, and gels containing collagenase, remove necrotic tissue from venous leg ulcers, pressure ulcers, burn lesions, and partial-thickness burns. These products facilitate expedited wound healing and treat diabetic foot ulcers with efficacy. The products containing collagenase are readily obtainable and widely employed by medical practitioners. It is expected that the increasing incidence of pressure ulcers, ulcers in diabetic feet, and venous leg ulcers will fuel the expansion of this market segment.Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region dominated the market with the maximum revenue share. An expansion in the majority of sports injuries & road accidents and the existence of several key players are factors anticipated to drive the market in North America. The US held the dominant revenue share in North America. Moreover, product launches, conferences regarding the clinical outcome, acquisitions, and collaborations in the market will likely boost market growth over the forecast period.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd.
Scope of the Study
Market Segments Covered in the Report:
By End-use- Hospitals
- Homecare
- Others
- Chronic Wounds- Diabetic Foot Ulcers
- Pressure Ulcers
- Venous Leg Ulcers
- Others
- Acute Wounds- Burns
- Others
- Collagenase Product
- Papain Product
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- ConvaTec Group PLC
- Smith & Nephew PLC
- Molnlycke Health Care AB
- Integra LifeSciences Holdings Corporation
- B.Braun Melsungen AG
- Coloplast Group
- Medline Industries, Inc.
- 3M Company
- HARTMANN Group (Paul Hartmann AG)
- MediWound Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Enzymatic Wound Debridement Market by End-use
Chapter 5. Global Enzymatic Wound Debridement Market by Type
Chapter 6. Global Enzymatic Wound Debridement Market by Product
Chapter 7. Global Enzymatic Wound Debridement Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- ConvaTec Group PLC
- Smith & Nephew PLC
- Molnlycke Health Care AB
- Integra LifeSciences Holdings Corporation
- B. Braun Melsungen AG
- Coloplast Group
- Medline Industries, Inc.
- 3M Company
- HARTMANN Group (Paul Hartmann AG)
- MediWound Ltd
Methodology
LOADING...
